Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of decitabine-treated AML cell line panel

ABSTRACT: We assessed differential RNA expression and stability by treatment condition (decitabine and DMSO) in each cell line.

ORGANISM(S): Homo sapiens

PROVIDER: GSE222822 | GEO | 2023/01/13

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Gene expression profiling in primary AML cells treated with decitabine and cytarabine

Project description:Acute myeloid leukemia (AML), and other myeloid malignancies, are frequently treated with hypomethylating agents like decitabine. Alterations in the epigenome, induced by decitabine, are likely to result in gene expression changes. The effects of decitabine have not been systemically studied using primary AML samples. We cultured 18 different primary AML samples for 7 days, the last 3 days of which included 100 nM decitabine (DAC) or 100 nm cytarabine (AraC). We hypothesized that decitabine treatment would result in detectable and consistent gene expression changes. For comparison, we also analyzed mRNA from cells treated with DMSO control (mock) and mRNA from uncultured cells taken at the time of diagnosis.

2012-12-18 | E-GEOD-40442 | biostudies-arrayexpress

Transient low-dose decitabine treatment of primary AML samples

Project description:Genome-wide DNA methylation profiling of primary AML samples treated with 100nM decitabine (DAC), cytarabine (AraC), or DMSO. Eight distinct AML samples were grown using an in vitro stromal co-culture system for 4 days and then treated with either DAC, Ara-C or DMSO for 3 days. DNA was prepared for genome-wide methylation analysis with the Illumina Infinium 450k Human DNA methylation BeadChip. DNA from each sample/treatment was analyzed on duplicate arrays.

2012-12-18 | GSE40870 | GEO

Transient low-dose decitabine treatment of primary AML samples

2012-12-18 | E-GEOD-40870 | biostudies-arrayexpress

Gene expression profiling in primary AML cells treated with decitabine and cytarabine

2012-12-18 | GSE40442 | GEO

DA Methylation patterns in decitabine treated 786-0 cells

Project description:Genome-wide DNA methylation profiling of 786-0 RCC cells treated with decitabine (100nM and 300nM) or DMSO vehicle. The Illumina Infinium HumanMethylation EPIC BeadChip was used to obtain DNA methylation profiles across approximately 850K CpGs.

2020-06-01 | GSE146179 | GEO

Decitabine alters DNA methylation in AML patients

Project description:Sequential assessment of global mRNA expression in myeloblasts isolated from peripheral blood of eight AML patients treated with Decitabine within a phase II study (trial 00331). Total RNA was isolated after enrichment of peripheral blood myeloblasts directly before and directly after (median day 3) Decitabine administration

2012-12-12 | E-MEXP-3737 | biostudies-arrayexpress

Effect of decitabine, carboplatin and their combination on gene expression in the YB5 colon cancer cell line.

Project description:YB5 cell line is a clonal derivative of the SW48 colon cancer cell line that contains a single copy of a green fluorescent protein (GFP) reporter silenced by CpG methylation at its CMV promoter. We treated the YB5 cells with decitabine (5-aza-2’-deoxycytidine), carboplatin and the combination of decitabine plus carboplatin and analyzed the effects of the drugs on gene expression. YB5 cells in the early log phase of growth were seeded at 3.5 million in 20 ml of culture medium in 10 cm diameter tissue culture plates at day 0. The cells were treated with 20 microliters of decitabine (final concentration 25 nM), carboplatin (final concentration 20 uM) or both at days 1, 2, 3 and 4. Control cells were treated with 20 microliters of diluent (DMSO). The cells were harvested at day 6. Total RNA was extracted by TRIZOL, labeled with Cy5 (control cells) or Cy3 (treated cells) and hybridized on Agilent Whole Genome Array (G4112F). Raw data from the Agilent scanner were loess normalized using Bioconductor packages limma and agilp.

2015-09-08 | E-GEOD-66279 | biostudies-arrayexpress

Expression data from decitabine-treated and non-treated BR5FVB1-Akt cells

Project description:The DNA methyl transferase inhibitor decitabine regulates gene expression in cancer cells. We used microarrays to detail the globle programming of gene expression, and identified a distinct class of immunoregulartory genes up-regulated upon decitabine treatment in ovarian cancer cells.

2015-06-03 | GSE69454 | GEO

Transcriptional profile of AML xenografts treated with either PBS or a combination of decitabine and cytarabine

Project description:The Affymetrix Human Genome U133 Plus 2.0 Array was used to examine the Genome wide transcriptional changes which follow the treatment of AML xenografts with either PBS control or combination of decitabine (DAC) and cytarabine (Ara-C). Animals were treated with PBS, DAC alone, Ara-C alone, DAC and Ara-C combined (D+A), DAC followed by Ara-C (D/A) or Ara-C followed by DAC (A/D). PBS vs each drug combination

2013-03-06 | E-GEOD-44857 | biostudies-arrayexpress

RNA-seq of YB5 and MCF7 treated with different doses of decitabine

Project description:RNA-seq was performed after YB5 cells were treated with 1uM decitabine, and MCF7 cells were treated with 100nM decitabine

2017-01-31 | GSE74251 | GEO